Redefining the treatment paradigm to eliminate cancer as a cause of death

Our approach

Even as research and development continues to break boundaries in how we understand and fight cancer, there are still more than eight million lives lost every year to the disease.

At AstraZeneca, we are committed to advancing the science of oncology to deliver life-changing medicines to patients most in need. With a combination-focused pipeline that exploits the power of four scientific platforms to help address unmet clinical needs in a host of cancers, we are motivated by a dedication to the scientific discovery and collaboration that will one day help eliminate cancer as a cause of death.

Our scientific platforms

We've decided to concentrate on four scientific platforms that we believe give us the best chance in finding routes to effective medicines in the most efficient way.


Using the body's immune system to help fight cancer

  • Tumour drivers and resistance

    Developing therapies that target specific mutations to attack cancer cells

    Watch video
  • DNA damage response

    Targeting the DNA repair process to block tumour cells' ability to reproduce

  • Antibody-drug conjugates

    Arming antibodies with cancer-killing agents for specific tumour targeting

    Watch video

Four key disease areas

There are many types of cancer disease. For us to be most effective, we've chosen to concentrate on four key diseases.

What we're working on

As part of our commitment to oncology, we're constantly working on new and exciting streams of work. Here are just a few of what we're up to at the moment.

Collaboration in Oncology

To eradicate cancer as a cause of death, we understand that we cannot work alone. Improving patient outcomes requires a collaborative approach to research and development.

Our Oncology pipeline

Our robust pipeline includes investigational therapies in varied stages of clinical development, from recently approved products to earlier-stage molecules in clinical trials. We aspire to transform the lives of cancer patients, working to eliminate cancer as a cause of death in the future.

Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).

Oncology (as at 14 February 2019)

Phase I

Phase I

  • AZD0156 solid tumours
  • AZD1390 glioblastoma
  • AZD4573 haematalogical malignancies
  • AZD4785 solid tumours
  • AZD5153 solid tumours
  • AZD5991 haematalogical malignancies
  • AZD9496 oestrogen receptor +ve breast cancer
  • AZD9833 oestrogen receptor +ve breast cancer
  • Calquence + AZD6738 haematological malignancies
  • Calquence + danvatirsen haematological malignancies
  • Imfinzi + Iressa non-small cell lung cancer
  • Imfinzi + RT (platform) CLOVER locally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + adavosertib solid tumours
  • Imfinzi + azacitidine myelodysplastic syndrome
  • Imfinzi + dabrafenib + trametinib melanoma
  • Imfinzi + selumetinib solid tumours
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi + tremelimumab + chemotherapy 1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • MEDI2228 multiple myeloma
  • MEDI3726 prostate cancer
  • MEDI5083 solid tumours
  • MEDI5752 solid tumours
  • MEDI7247 haematological malignancies
  • oleclumab solid tumours
  • oleclumab + AZD4635 EGFRm NSCLC
  • oleclumab + Tagrisso EGFRm NSCLC

Phase II

Phase II

  • AZD2811 solid tumours
  • AZD4547 solid tumours
  • AZD4635 solid tumours
  • AZD6738 solid tumours
  • AZD8186 solid tumours
  • Imfinzi + AZD5069 or Imfinzi + danvatirsen head and neck squamous cell carcinoma, bladder and NSCLC
  • Imfinzi + Lynparza BAYOU 1st-line unresectable stage IV bladder cancer
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Imfinzi + MEDI0680 solid tumours
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + oleclumab solid tumours
  • Imfinzi + tremelimumab biliary tract, oesophageal
  • Imfinzi + tremelimumab gastric cancer
  • Lynparza + AZD6738 gastric cancer
  • Lynparza + AZD6738 or Lynparza + adavosertib VIOLETTE breast cancer
  • Lynparza + Imfinzi MEDIOLA ovarian cancer, breast cancer, gastic cancer and small-cell lung cancer
  • Lynparza + adavosertib solid tumours
  • Tagrisso + or selumetinib or savolitinib) TATTON advanced EGFRm non-small cell lung cancer
  • adavosertib + chemotherapy ovarian cancer
  • capivasertib breast cancer

Phase III

Phase III

  • Calquence relapsed/refractory mantle cell lymphoma
  • Imfinzi + tremelimumab DANUBE 1st-line bladder cancer
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab NEPTUNE 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab + CRT ADRIATIC LD-SCLC
  • Imfinzi + tremelimumab + SoC CASPIAN 1st-line small cell lung cancer
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Imfinzi + tremelimumab + chemo POSEIDON 1st-line non-small cell lung cancer
  • Lumoxiti PLAIT 3rd-line hairy cell leukaemia
  • Lynparza + cediranib CONCERTO recurrent platinum-resistant ovarian cancer
  • savolitinib SAVOIR papillary renal cell carcinoma
  • selumetinib SPRINT paediatric neurofibromatosis type-1

LCM Projects

LCM Projects

  • Calquence 1st-line chronic lymphocytic leukaemia
  • Calquence relapsed/refractory chronic lymphocytic leukaemia
  • Calquence relapsed/refractory chronic lymphocytic leukaemia, high risk
  • Calquence haematological malignancies
  • Calquence 1st-line mantle cell lymphoma
  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Imfinzi PACIFIC locally advanced (stage III) NSCLC
  • Imfinzi solid tumours
  • Imfinzi PEARL (China) 1st-line non-small cell lung cancer
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) NSCLC
  • Imfinzi + CRT PACIFIC-5 (China) locally-advanced (stage III) NSCLC
  • Imfinzi + CTx NIAGARA muscle invasive bladder cancer
  • Imfinzi + CTx neoadjuvant AEGEAN locally-advanced (stage III) NSCLC
  • Imfinzi + VEGF + TACE EMERALD-1 locoregional hepatocellar carcinoma
  • Lynparza PROfound prostate cancer
  • Lynparza SOLO-1 1st-line BRCAm ovarian cancer
  • Lynparza SOLO-2 2nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza OlympiAD gBRCA metastatic breast cancer
  • Lynparza POLO pancreatic cancer
  • Lynparza SOLO-3 gBRCA PSR ovarian cancer
  • Lynparza + abiraterone PROpel prostate cancer
  • Tagrisso ADAURA adjuvant EGFRm non-small cell lung cancer
  • Tagrisso FLAURA 1st-line advanced EGFRm non-small cell lung cancer
  • Tagrisso LAURA stage 3 EGFRm non-small cell lung cancer

Our Oncology medicines

Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations.

You should visit your local AstraZeneca site to find out more about our medicines in your country. In some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.

  • Arimidex anastrozole
  • Calquence acalabrutinib
  • Casodex, Cosudex bicalutamide
  • Faslodex fulvestrant
  • Imfinzi durvalumab
  • Iressa gefitinib
  • Lynparza olaparib
  • Tagrisso osimertinib
  • Zoladex goserelin acetate implant

Veeva ID: Z4-12940   
Date of next review: September 2020